Table 1:
Demographic, clinical, and laboratory characteristics of the study cohort according to viral load threshold a
| VL≤40 (Copies/mL) (n=203) | VL > 40 & ≤1,000 (Copies/mL) (n=109) | VL>1,000 (Copies/mL) (n=82) | Total Cohort (n=394) | |
|---|---|---|---|---|
| Continuous Measures: Median(range) | ||||
| Age | 42.2 (26.5, 68.9) | 41.5 (22.2, 72.6) | 38.8 (18.6, 69.8) | 41.7 (18.6, 72.6) |
| Years on 1st-line | 2.7 (0.5, 10.6) | 2.7 (0.6, 10.4) | 3.3 (0.7, 8.7) | 2.9 (0.5, 10.6) |
| Years on 2nd line | 2.4 (0.5, 8.8) | 1.8 (0.4, 7.5) | 1.3 (0.5, 7.2) | 1.9 (0.4, 8.8) |
| Days of TI on 1st-line b | 40 (16, 110) | 54 (14, 448) | 72 (14, 382) | 49 (14, 448) |
| Days of TI on 2nd-line b | 45.5 (14, 370) | 50 (44, 56) | 48 (35, 126) | 46.5 (14, 370) |
| Days of TI between 1st and 2nd-line b | 65 (14, 399) | 58 (24, 165) | 106 (14, 130) | 69 (14, 399) |
| CD4 Count (cells/μL) | 313 (35, 1424) | 278 (31, 1377) | 171.5 (8, 855) | 282 (8, 1424) |
| CD4 Percent | 19 (2, 40) | 16 (2, 36) | 14 (1, 35) | 17 (1, 40) |
| Categorical Measures: number, % | ||||
| Female | 130, 64% | 62, 57% | 46, 56% | 239, 60% |
| WHO Stage 1 | 30, 15% | 12, 11% | 12, 15% | 54, 14% |
| WHO Stage 2 | 35, 17% | 21, 20% | 9, 11% | 65, 17% |
| WHO Stage 3 | 86, 43% | 50, 47% | 50, 61% | 186, 48% |
| WHO Stage 4 | 50, 25% | 24, 22% | 11, 13% | 85, 22% |
| >One 2nd-Line Regimen | 50, 25% | 25, 23% | 19, 23% | 94, 24% |
| >One 1st-Line Regimen | 89, 44% | 38, 35% | 28, 34% | 155, 39% |
| Unique ARV regimen | 7, 3% | 3, 3% | 5, 6% | 15, 4% |
| TI on 1st-line b | 19, 9% | 11, 10% | 13, 16% | 43, 11% |
| TI on 2nd-line b | 6, 3% | 2, 2% | 4, 5% | 12, 3% |
| TI between 1st-and 2nd-line b | 6, 3% | 3, 3% | 6, 7% | 15, 4% |
| Incomplete 1-Month Adherence | 6, 3% | 3, 3% | 4, 5% | 13, 3% |
| Incomplete 7-day Adherence | 16, 8% | 1, 1% | 6, 7% | 23, 6% |
| TB treatment on 2nd-line | 12, 6% | 7, 6% | 12, 15% | 31, 8% |
| Previous Pregnancies (n=238 females) | 46, 35% | 18, 29% | 26, 57% | 90, 38% |
| pMTCT c | 7, 15% | 6, 33% | 1, 4% | 14, 16% |
a
Measures presented as median (range) for continuous and n, % for categorical measures;
b
TI times are summarized only among those who had a TI;
c
pMTCT data unknown for 2/90.
Abbreviations: ARV, antiretroviral; pMTCT, prevention of mother to child transmission; TB, tuberculosis; TI, treatment interruption; VL, viral load. Odds ratios, confidence intervals and p-values for comparisons of the VL groups are provided in Supplemental Table 1.